Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Diclofenac. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 8/20 | 0.89 |
| ▸ | PTGS1 known ✓ | P23219 | 2/20 | 0.89 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.89 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.89 |
| ▸ | GAA | P10253 | 1/20 | 0.89 |
| ▸ | TSHR | P16473 | 1/20 | 0.89 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.89 |
| ▸ | BLM | P54132 | 1/20 | 0.89 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.89 |
| ▸ | CXCL8 | P10145 | 4/20 | 0.84 |
| ▸ | TTR | P02766 | 3/20 | 0.84 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.84 |
| ▸ | UGT1A9 | O60656 | 1/20 | 0.84 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.84 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.84 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.84 |
| ▸ | ALB | P02768 | 1/20 | 0.84 |
| ▸ | UGT1A6 | P19224 | 1/20 | 0.84 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.84 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diclofenac SCHEMBL15512318 | 0.99 | PTGS2 (0.87) | PTGS2CYP2C9PTGS1CYP3A4GAA | |
| Diclofenac SCHEMBL29350388 | 0.94 | PTGS2 (1.00) | PTGS2CYP2C9PTGS1CYP3A4GAA | |
| Diclofenac SCHEMBL1244510 | 0.94 | PTGS2 (1.00) | PTGS2CYP2C9PTGS1CYP3A4GAA | |
| Diclofenac SCHEMBL24009 | 0.94 | PTGS2 (1.00) | PTGS2CYP2C9PTGS1CYP3A4GAA | |
| Diclofenac SCHEMBL7083032 | 0.93 | PTGS2 (0.97) | PTGS2CYP2C9PTGS1CYP3A4GAA | |
| Diclofenac SCHEMBL6509233 | 0.93 | PTGS2 (0.97) | PTGS2CYP2C9PTGS1CYP3A4GAA | |
| Diclofenac SCHEMBL21048102 | 0.93 | PTGS2 (0.97) | PTGS2CYP2C9PTGS1CYP3A4GAA | |
| Diclofenac SCHEMBL1232980 | 0.93 | PTGS2 (0.97) | PTGS2CYP2C9PTGS1CYP3A4GAA | |
| Diclofenac SCHEMBL40784 | 0.92 | PTGS2 (0.94) | PTGS2CYP2C9PTGS1CYP3A4GAA | |
| Diclofenac SCHEMBL29385384 | 0.92 | PTGS2 (0.94) | PTGS2CYP2C9PTGS1CYP3A4GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024062349-A1 | HYDROALCOHOLIC TOPICAL DICLOFENAC FORMULATIONS | HALEON CH SARL (CH) | 2024-03-28 | — | — | WO | claimed |
| EP-4323005-A1 | DRUG DELIVERY VIA MONOACYLGLYCEROL AND FREE FATTY ACID-BASED COMPOSITIONS | GlycosBio Inc. (US) | 2024-02-21 | — | — | EP | disclosed |
| US-20240050422-A1 | DRUG DELIVERY VIA MONOACYLGLYCEROL AND FREE FATTY ACID-BASED COMPOSITIONS | GLYCOSBIO INC (US) | 2024-02-15 | — | — | US | disclosed |
| US-20230356232-A1 | PRODUCTION OF ENCAPSULATED NANOPARTICLES AT COMMERCIAL SCALE | ICEUTICA PTY LTD. (AU) | 2023-11-09 | — | — | US | disclosed |
| US-20230346697-A1 | ANTIMICROBIAL AND ANTI-INFLAMMATORY COMPOSITIONS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-11-02 | — | — | US | disclosed |
| US-11723864-B2 | Antimicrobial and anti-inflammatory compositions | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2023-08-15 | — | — | US | disclosed |
| US-20230133244-A1 | Method for the Production of Commercial Nanoparticle and Microparticle Powders | ICEUTICA PTY LTD. (AU) | 2023-05-04 | — | — | US | disclosed |
| US-20200390710-A1 | Method for the Production of Commercial Nanoparticle and Microparticle Powders | ICEUTICA PTY LTD. (AU) | 2020-12-17 | — | — | US | disclosed |
| EP-3687461-A1 | PRESERVATIVE REMOVAL FROM EYE DROPS CONTAINING HYDROPHILIC DRUGS | University of Florida Research Foundation, Inc. (US) | 2020-08-05 | — | — | EP | disclosed |
| EP-2421510-B1 | PRODUCTION OF ENCAPSULATED NANOPARTICLES AT COMMERCIAL SCALE | ICEUTICA PTY LTD (AU) | 2019-07-31 | — | — | EP | disclosed |
| EP-2421510-A1 | PRODUCTION OF ENCAPSULATED NANOPARTICLES AT COMMERCIAL SCALE | Iceutica Pty Ltd. (AU) | 2012-02-29 | — | — | EP | disclosed |
| EP-2421511-A1 | METHOD FOR THE PRODUCTION OF COMMERCIAL NANOPARTICLE AND MICROPARTICLE POWDERS | Iceutica Pty Ltd. (AU) | 2012-02-29 | — | — | EP | disclosed |
| EP-2421525-A1 | A NOVEL FORMULATION OF DICLOFENAC | Iceutica Pty Ltd. (AU) | 2012-02-29 | — | — | EP | disclosed |
| WO-2010121327-A1 | A NOVEL FORMULATION OF DICLOFENAC | ICEUTICA PTY LTD (AU) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010121323-A1 | METHOD FOR THE PRODUCTION OF COMMERCIAL NANOPARTICLE AND MICROPARTICLE POWDERS | ICEUTICA PTY LTD (AU) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010121322-A1 | PRODUCTION OF ENCAPSULATED NANOPARTICLES AT COMMERCIAL SCALE | ICEUTICA PTY LTD (AU) | 2010-10-28 | — | — | WO | disclosed |
| EP-2054052-A1 | DRUG COMBINATION PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USING THEM | Vicus Therapeutics SPE 1, LLC (US) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008014471-A1 | DRUG COMBINATION PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USING THEM | VICUS THERAPEUTICS SPE 1, LLC (US) | 2008-01-31 | — | — | WO | disclosed |
| WO-1995033492-A9 | METHODS AND COMPOSITIONS FOR MODULATION OF WOUND HEALING | — | 1996-02-29 | — | — | WO | disclosed |
| WO-1995033492-A1 | METHODS AND COMPOSITIONS FOR MODULATION OF WOUND HEALING | HOUSTON BIOTECHNOLOGY INCORPORATED (US) | 1995-12-14 | — | — | WO | disclosed |